Drug Accountability Record

Forms and Documents

Forms and supporting documents for this ICR

Document	Type	Status	Availability
Form 1 Accountability Record/TID Transfer Form	Form and Instruction	New	Available
SSA.doc	Supporting Statement A	Uploaded 2007-11-01	Available

IC Document Collections

Information collection document groups

IC ID	Collection	Type	Status	Form
7263	Drug Accountability Record		Removed
182782	Accountability Record/TID Transfer Form	Form and Instruction	New

ICR Details

OMB Control No: 0925-0240	ICR Reference No: 200711-0925-003
Status: Historical Inactive	Previous ICR Reference No: 200404-0925-004
Agency/Subagency: HHS/NIH	Agency Tracking No:
Title: Drug Accountability Record
Type of Information Collection: Extension without change of a currently approved collection	Common Form ICR:  No
Type of Review Request: Regular
OIRA Conclusion Action: Withdrawn and continue	Conclusion Date: 01/07/2008
	Date Received in OIRA: 11/19/2007
Terms of Clearance: This ICR is withdrawn, per NIH request. Should NIH resubmit this ICR, NIH shall ensure that the changes in burden hours and costs are properly reported in ROCIS (the burden hours and costs were not reported correctly in this submission).

table that charts list comparision

	Inventory as of this Action	Requested	Previously Approved
Expiration Date	11/30/2007	36 Months From Approved	02/29/2008
Responses	66,339	0	66,339
Time Burden (Hours)	3,378	0	3,378
Cost Burden (Dollars)	0	0	0

---

Abstract: The NCI, as a sponsor of investigational drug trials, has the responsibility to assure to the FDA that systems for drug accountability are being maintained by investigators in its clinical trials program. The data obtained from the drug accountability record is used to track the dispensing of investigational anticancer drugs from receipt from NIC to dispensing or administration to patients. NCI and/or its auditors for compliance reasons use this information.

---

Authorizing Statute(s): US Code: 42 USC 413(b)(1) Name of Law: Public Health Service Act
   US Code: 21 USC 312.1; 312.34; 312.53; 312.58 Name of Law: Investigational New Drug Application
  

Citations for New Statutory Requirements: None

---

Associated Rulemaking Information
RIN:	Stage of Rulemaking:	Federal Register Citation:	Date:
	Not associated with rulemaking

---

Federal Register Notices & Comments
60-day Notice:	Federal Register Citation:	Citation Date:
	72 FR 45251	08/13/2007
30-day Notice:	Federal Register Citation:	Citation Date:
	72 FR 61889	11/01/2007
Did the Agency receive public comments on this ICR? No

---

Number of Information Collection (IC) in this ICR: 1

table that charts list of burden

IC Title	Form No.	Form Name
Accountability Record/TID Transfer Form	1, 2	DARF ,   TID Transfer Form
Drug Accountability Record	NIH-2564, NIH-2564-1

---

Burden increases because of Program Change due to Agency Discretion: No

Burden Increase Due to:

Burden decreases because of Program Change due to Agency Discretion: Yes

Burden Reduction Due to: Miscellaneous Actions

Short Statement: The increase in burden from the previous request is an adjustment. The increase in burden reflects an increase in the number of IND's, protocols, investigators, and drug shipments.

---

Annual Cost to Federal Government: $500

Does this IC contain surveys, censuses, or employ statistical methods? No

Is the Supporting Statement intended to be a Privacy Impact Assessment required by the E-Government Act of 2002? No

Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]? Uncollected

Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]? Uncollected

Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)? Uncollected

Is this ICR related to the Pandemic Response? Uncollected

---

Common Form ICR:  No

---

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).

The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:

(a) It is necessary for the proper performance of agency functions;

(b) It avoids unnecessary duplication;

(c) It reduces burden on small entities;

(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;

(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;

(f) It indicates the retention periods for recordkeeping requirements;

(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:

(i) Why the information is being collected;

(ii) Use of information;

(iii) Burden estimate;

(iv) Nature of response (voluntary, required for a benefit, or mandatory);

(v) Nature and extent of confidentiality; and

(vi) Need to display currently valid OMB control number;

(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.

(i) It uses effective and efficient statistical survey methodology (if applicable); and

(j) It makes appropriate use of information technology.

If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.

Certification Date: 11/19/2007

---